The STOP-T1D Prevention Study is now closed. The study closed because it did not meet its recruitment timeline. There were no safety concerns. Researchers remain excited about anti-thymocyte globulin (ATG) in Stage 2 of type 1 diabetes (T1D). TrialNet investigators are developing a new study to test ATG at this early stage of T1D.

About the Study

TrialNet researchers set out to test a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it could delay or prevent type 1 diabetes in people with a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk was defined as having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker in lab results. In an earlier TrialNet study for people newly diagnosed with Stage 3 T1D, low-dose ATG preserved insulin production and improved Hemoglobin A1c for 2 years.

For Study Participants

We thank our STOP-T1D participants for their dedication to advancing T1D research and encourage them to take part in the Pathway to Prevention Monitoring Study if they have not progressed to Stage 3 T1D. Those who are diagnosed with Stage 3 T1D can be part of TrialNet’s Long-Term Investigational Follow Up (LIFT) study. Participants in either study continue to provide valuable scientific information that will help answer important questions about T1D.